| Project/Area Number |
21591822
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Kitasato University |
|---|
Principal Investigator |
IYODA Akira 北里大学, 医学部, 准教授 (10302548)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SATOH Yukitoshi 北里大学, 医学部, 教授 (90321637)
AMANO Hideki 北里大学, 医学部, 助教 (60296481)
根津 賢司 北里大学, 医学部, 講師 (10530850)
小川 史洋 北里大学, 医学部, 助教 (80383610)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 肺癌 / テーラーメイド治療 / 予後 / 組織型 |
|---|
| Research Abstract |
We analyzed LCNEC gene expression, gene mutation and immunohistochemical expression of known molecular targets and compared expression to that of lung adenocarcinomas. We analyzed 13 patients with primary LCNEC and 14 patients with adenocarcinoma(AC). We evaluated immunohistochemical(IHC) expression for c-KIT, human epidermal growth factor receptor type 2(HER2), and vascular endothelial growth factor(VEGF), gene mutation for EGFR, K-ras and c-kit, and gene expression using fluorescence in situ hybridization(FISH) for EGFR. In cases with LCNEC, the IHC expression of c-KIT, HER2, and VEGF were 76.9%, 30.8%, and 100%, respectively. There was a significant difference in IHC expression in c-KIT and HER2 between LCNEC and AC. Two cases of LCNEC had overexpression of HER2, and EGFR gene mutation was greater in the AC group, with only a single EGFR mutation(exon 18) identified in the LCNEC group. Although LCNEC had a higher rate of expression of c-KIT by IHC, no c-kit gene mutations were found. These findings suggest a potential role for Anti-VEGF, Anti-c-KIT, and possibly Anti-HER2 targeted agents in the treatment of LCNEC.
|
